Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

266 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).
Ghielmini M, Vitolo U, Kimby E, Montoto S, Walewski J, Pfreundschuh M, Federico M, Hoskin P, McNamara C, Caligaris-Cappio F, Stilgenbauer S, Marcus R, Trneny M, Dreger P, Montserrat E, Dreyling M; Panel Members of the 1st ESMO Consensus Conference on Malignant Lymphoma. Ghielmini M, et al. Ann Oncol. 2013 Mar;24(3):561-76. doi: 10.1093/annonc/mds517. Epub 2012 Nov 21. Ann Oncol. 2013. PMID: 23175624 Free PMC article.
Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conference.
Dreyling M, Hoster E, Bea S, Hartmann E, Horn H, Hutter G, Salaverria I, Pott C, Trneny M, Le Gouill S, Cortelazzo S, Szymczyk M, Jurczak W, Shpilberg O, Ribrag V, Hermine O; European MCL Network. Dreyling M, et al. Among authors: shpilberg o. Leuk Lymphoma. 2010 Sep;51(9):1612-22. doi: 10.3109/10428194.2010.496507. Leuk Lymphoma. 2010. PMID: 20629519 Review.
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Coiffier B, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, Rule S, Teixeira A, Walewski J, de Vos S, Crump M, Shpilberg O, Esseltine DL, Zhu E, Enny C, Theocharous P, van de Velde H, Elsayed YA, Zinzani PL; LYM-3001 study investigators. Coiffier B, et al. Among authors: shpilberg o. Lancet Oncol. 2011 Aug;12(8):773-84. doi: 10.1016/S1470-2045(11)70150-4. Epub 2011 Jul 1. Lancet Oncol. 2011. PMID: 21724462 Clinical Trial.
Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma.
Hellmann A, Rule S, Walewski J, Shpilberg O, Feng H, van de Velde H, Patel H, Skee DM, Girgis S, Louw VJ. Hellmann A, et al. Among authors: shpilberg o. Clin Pharmacokinet. 2011 Dec 1;50(12):781-91. doi: 10.2165/11594410-000000000-00000. Clin Pharmacokinet. 2011. PMID: 22087865 Clinical Trial.
266 results